New hope for myeloma patients too old for transplant?
NCT ID NCT05272826
First seen Oct 31, 2025
Summary
This study tests a combination of four drugs—iberdomide, bortezomib, dexamethasone, and isatuximab—for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this treatment can shrink or eliminate the cancer. About 75 participants aged 65 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cross Cancer Institute
RECRUITINGEdmonton, Alberta, T6G 1Z2, Canada
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Maisonneuve-Rosemont
RECRUITINGMontreal, Quebec, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
London Health Sciences Centre
RECRUITINGLondon, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
McGill University Health Centre
RECRUITINGMontreal, Quebec, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NL Health Services
RECRUITINGSt. John's, Newfoundland and Labrador, A1B 3V6, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Princess Margaret Hospital
RECRUITINGToronto, Ontario, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
QEII Health Science Centre
RECRUITINGHalifax, Nova Scotia, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iberdomide, bortezomib, dexamethasone, and isatuximab
What this could lead to
If successful, this could offer a new, effective treatment option for older adults with multiple myeloma who cannot undergo a stem cell transplant.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 75 participants, so results may not apply to everyone. The drug combination may cause side effects or not work as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.